Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

Next Previous
X
Search
Trial Profile

A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OCX 191 (Primary) ; Cisplatin
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer; Vulvovaginal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Sep 2023 Planned End Date changed from 21 Jun 2024 to 21 Sep 2024.
    • 23 Sep 2023 Planned End Date changed from 21 Jun 2024 to 21 Sep 2024.
    • 23 Jun 2023 Planned End Date changed from 23 Jul 2023 to 21 Jun 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top